GGrantIndex
Sort

64,565 grants matching drug discovery

Development of a novel Alzheimer's disease therapeutic targeting tau

$998,691
Glenn Larsen · Aquinnah Pharmaceuticals, Inc. · R44 · FY2025 · AG

Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening

$998,661
Steven Joseph Darnell · Dnastar, Inc. · R44 · FY2022 · AI

Rapid structure-based software to enhance antibody affinity and developability for high-throughput screening

$998,661
Steven Joseph Darnell · Dnastar, Inc. · R44 · FY2021 · AI

Pacific Northwest Advanced Compound Identification Core

$998,631
Thomas O Metz · Battelle Pacific Northwest Laboratories · U2C · FY2019 · ES

Gulf Coast Consortia (GCC) Research Evaluation and Commercialization Hub

$998,317
Peter J Davies · Texas A&M University Health Science Ctr · U01 · FY2025 · GM

A 3D vascularized islet biomimetic to model type 1 diabetes

$998,312
Maike Sander · University Of California, San Diego · UH3 · FY2023 · DK

SBIR Phase II: Fluorescent Polymeric Nanoparticles

$998,241
Lawrence F Hancock · Nomadics, Inc · · FY2003 · TIP

UC BRAID Center for Accelerated Innovation

$998,230
Michael J Palazzolo · University Of California Los Angeles · U54 · FY2019 · HL

Amish Connectome Project on Mental Illness

$998,092
L. Elliot Hong · University Of Maryland Baltimore · U01 · FY2016 · MH

Depletion of Dendritic Cells by Immunotoxin as Therapy for Myocardial Infarction

$998,051
Michael W Fanger · Celdara Medical, Llc · R44 · FY2013 · HL

MetaboQuest: A Suite of Tools for Metabolite Annotation

$997,931
Dawit Mengistu · Omicscraft, Llc · R44 · FY2023 · GM

MetaboQuest: A Suite of Tools for Metabolite Annotation

$997,931
Dawit Mengistu · Omicscraft, Llc · R44 · FY2022 · GM

Development of Broad Spectrum Host Oriented Therapeutic Antibodies against Influe

$997,899
Wu-Bo Li · Functional Genetics, Inc. · R44 · FY2012 · AI

Novel small-molecule therapies for CF

$997,891
Alan S Verkman · University Of California, San Francisco · P30 · FY2007 · DK

Heterocyclic Inhibitors of QcrB as Novel Drugs for Tuberculosis

$997,875
Thomas Joseph Hannan · Fimbrion Therapeutics, Inc. · R44 · FY2023 · AI

The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable Mutations

$997,800
William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2025 · CA

The von Hippel-Lindau Tumor Suppressor Gene and Kidney Cancer: Insights into Oxygen Sensing and Treating Cancers Caused by Undruggable Mutations

$997,800
William G Kaelin · Dana-Farber Cancer Inst · R35 · FY2023 · CA

SBIR Phase II: A novel 3D bioprinting system for rapid high-throughput tissue fabrication

$997,692
Wei Zhu · Allegro 3d, Inc · · FY2021 · TIP

Inhibition Of Renal Injury

$997,543
Robert A Star · National Institute Of Diabetes And Digestive And Kidney Diseases · ZIA · FY2018 · DK

Deciphering the physiological role and interplay between ubiquitination and phosphorylation pathways to guide targeted cancer therapies

$997,500
Wenyi Wei · Beth Israel Deaconess Medical Center · R35 · FY2024 · CA

Integrated photoacoustic and fluorescence imaging system for anatomical, functional, and molecular characterization of murine models

$997,451
Sergey A Ermilov · Photosound Technologies, Inc. · R44 · FY2022 · OD

Defining T cell epitopes in Dengue virus infection

$997,328
Ramila Philip · Immunotope, Inc. · R44 · FY2014 · AI

Developmental Funds

$997,121
Stanton L Gerson · Case Western Reserve University · P30 · FY2020 · CA

Targeting superbugs: discovery and development of new broad-spectrum lipopeptides

$996,973
Jian Li · Monash University · R01 · FY2016 · AI

Development of Hepatitis C Virus Inhibitors

$996,920
Progenics Pharmaceuticals, Inc. · R44 · FY2005 · AI